Evaluating the Utilization of Biosimilars in Oncology: Managed Care Considerations

Program Description
The cost of cancer care greatly impacts the US healthcare system from a financial perspective. Biologic agents have shown efficacy in the treatment of many malignancies; however, they are associated with a high cost. The use of biosimilar agents in the oncology setting has the potential for cost savings and improved access to care. This program will review available oncology biosimilars, potential benefits and challenges in use, and will also emphasize payer strategies to help assist with access to care and prescriber acceptance into clinical practice.

Target Audience: Managed care and oncology pharmacists

Type of Activity: Application

Release date: November 3, 2021

Expiration date: November 3, 2022

Time to complete activity: 1.5 hours

Fee: Free


Educational Objectives

At the completion of this activity, participants will be able to:

• Analyze economic benefits of biosimilar use in oncology care.
• Investigate challenges of biosimilar uptake in clinical practice and considerations to reduce barriers to formulary and pathway inclusion.
• Explore payer strategies to manage the use of biosimilars in oncology care and improve patient access.